{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:44:25Z","timestamp":1793825065017,"version":"4.6.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis US LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.anai.2023.03.014","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:41:23Z","timestamp":1679445683000},"page":"44-51.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma"],"prefix":"10.1016","volume":"131","author":[{"given":"Daniel J.","family":"Jackson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard B.","family":"Bacharier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanda","family":"Phipatanakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Sher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Modena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changming","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myles","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Gall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leda P.","family":"Mannent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Laws","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juby A.","family":"Jacob-Nara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamo","family":"Deniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Lederer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Hardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.anai.2023.03.014_bib0001","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.5588\/ijtld.14.0170","article-title":"Global burden of asthma among children","volume":"18","author":"Asher","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.anai.2023.03.014_bib0002","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fped.2018.00186","article-title":"The burden of pediatric asthma","volume":"6","author":"Ferrante","year":"2018","journal-title":"Front Pediatr"},{"issue":"1","key":"10.1016\/j.anai.2023.03.014_bib0003","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5334\/aogh.2416","article-title":"Pediatric asthma: a global epidemic","volume":"85","author":"Serebrisky","year":"2019","journal-title":"Ann Glob Health"},{"key":"10.1016\/j.anai.2023.03.014_bib0004","unstructured":"Centers for Disease Control and Prevention. Vital signs. Available at: https:\/\/www.cdc.gov\/vitalsigns. Accessed October 12, 2022."},{"issue":"4","key":"10.1016\/j.anai.2023.03.014_bib0005","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1183\/09031936.00002108","article-title":"et al Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach","volume":"32","author":"Brand","year":"2008","journal-title":"Eur Respir J"},{"issue":"21","key":"10.1016\/j.anai.2023.03.014_bib0006","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.3390\/jcm11216558","article-title":"Risk factors affecting development and persistence of preschool wheezing: consensus document of the Emilia-Romagna Asthma (ERA) study group","volume":"11","author":"Grandinetti","year":"2022","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.anai.2023.03.014_bib0007","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/cea.12660","article-title":"Stability and predictiveness of multiple trigger and episodic viral wheeze in preschoolers","volume":"46","author":"van Wonderen","year":"2016","journal-title":"Clin Exp Allergy"},{"issue":"12","key":"10.1016\/j.anai.2023.03.014_bib0008","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.3390\/ph15121581","article-title":"Challenges in the pharmacotherapeutic management of pediatric asthma","volume":"15","author":"Ioniuc","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"10","key":"10.1016\/j.anai.2023.03.014_bib0009","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/S2213-2600(20)30399-4","article-title":"Advances in understanding and reducing the burden of severe asthma in children","volume":"8","author":"Pijnenburg","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"19","key":"10.1016\/j.anai.2023.03.014_bib0010","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1056\/NEJMoa1513737","article-title":"Patterns of growth and decline in lung function in persistent childhood asthma","volume":"374","author":"McGeachie","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.anai.2023.03.014_bib0011","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/ACI.0000000000000348","article-title":"Childhood asthma is a risk factor for the development of chronic obstructive pulmonary disease","volume":"17","author":"McGeachie","year":"2017","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2023.03.014_bib0012","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nri3786","article-title":"Type 2 inflammation in asthma\u2014present in most, absent in many","volume":"15","author":"Fahy","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.anai.2023.03.014_bib0013","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1089\/ped.2018.0886","article-title":"Asthma endotyping and biomarkers in childhood asthma","volume":"31","author":"Licari","year":"2018","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"issue":"2","key":"10.1016\/j.anai.2023.03.014_bib0014","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/cea.12880","article-title":"Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications","volume":"47","author":"Robinson","year":"2017","journal-title":"Clin Exp Allergy"},{"issue":"10","key":"10.1016\/j.anai.2023.03.014_bib0015","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1111\/all.13806","article-title":"Toward clinically applicable biomarkers for asthma: an EAACI position paper","volume":"74","author":"Diamant","year":"2019","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.anai.2023.03.014_bib0016","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.3892\/etm.2021.10698","article-title":"Biological therapies targeting the type 2 inflammatory pathway in severe asthma (Review)","volume":"22","author":"Fildan","year":"2021","journal-title":"Exp Ther Med"},{"issue":"7","key":"10.1016\/j.anai.2023.03.014_bib0017","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/cea.13954","article-title":"Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases","volume":"51","author":"Hamilton","year":"2021","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"10.1016\/j.anai.2023.03.014_bib0018","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12948-021-00146-9","article-title":"Defining type 2 asthma and patients eligible for dupilumab in Italy: a biomarker-based analysis","volume":"19","author":"Canonica","year":"2021","journal-title":"Clin Mol Allergy"},{"key":"10.1016\/j.anai.2023.03.014_bib0019","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention. 2021. Available at: https:\/\/ginasthma.org\/wp-content\/uploads\/2021\/05\/GINA-Main-Report-2021-V2-WMS.pdf. Accessed October 12, 2022."},{"issue":"5","key":"10.1016\/j.anai.2023.03.014_bib0020","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2023.03.014_bib0021","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Le Floc\u2019h","year":"2020","journal-title":"Allergy"},{"issue":"24","key":"10.1016\/j.anai.2023.03.014_bib0022","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa2106567","article-title":"Dupilumab in children with uncontrolled moderate-to-severe asthma","volume":"385","author":"Bacharier","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.anai.2023.03.014_bib0023","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/cpdd.798","article-title":"Pharmacokinetics, pharmacodynamics, safety, and tolerability of dupilumab in healthy adult subjects","volume":"9","author":"Li","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.anai.2023.03.014_bib0024","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.rmed.2019.05.005","article-title":"Monoclonal antibodies for severe asthma: pharmacokinetic profiles","volume":"153","author":"Matera","year":"2019","journal-title":"Respir Med"},{"issue":"8","key":"10.1016\/j.anai.2023.03.014_bib0025","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/psp4.12667","article-title":"Population pharmacokinetic analysis of dupilumab in adult and adolescent patients with asthma","volume":"10","author":"Zhang","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"26","key":"10.1016\/j.anai.2023.03.014_bib0026","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"issue":"10039","key":"10.1016\/j.anai.2023.03.014_bib0027","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.anai.2023.03.014_bib0028","unstructured":"Regeneron Pharmaceuticals, Inc., Dupixent (dupilumab) prescribing information. Available at: www.regeneron.com\/sites\/default\/files\/Dupixent_FPI.pdf. Accessed October 12, 2022."},{"issue":"6","key":"10.1016\/j.anai.2023.03.014_bib0029","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/cpt.1058","article-title":"Evaluation of potential disease-mediated drug-drug interaction in patients with moderate-to-severe atopic dermatitis receiving dupilumab","volume":"104","author":"Davis","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.anai.2023.03.014_bib0030","unstructured":"US Food and Drug Administration (FDA). Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review, dupilumab biologics license application number 761055Orig1s000. 2016. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761055Orig1s000ClinPharmR.pdf. Accessed October 12, 2022."},{"issue":"11","key":"10.1016\/j.anai.2023.03.014_bib0031","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/psp4.12136","article-title":"Exploratory population PK analysis of dupilumab, a fully human monoclonal antibody against IL-4R\u03b1, in atopic dermatitis patients and normal volunteers","volume":"5","author":"Kovalenko","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"5","key":"10.1016\/j.anai.2023.03.014_bib0032","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","article-title":"Ways to fit a PK model with some data below the quantification limit","volume":"28","author":"Beal","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.anai.2023.03.014_bib0033","unstructured":"US Food and Drug Administration (FDA), Dupixent (Dupilumab) Injection, for Subcutaneous Use: US Prescribing Information. 2017. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761055lbl.pdf. Accessed October 12, 2022."},{"issue":"14","key":"10.1016\/j.anai.2023.03.014_bib0034","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1073\/pnas.1324022111","article-title":"Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice","volume":"111","author":"Murphy","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"26","key":"10.1016\/j.anai.2023.03.014_bib0035","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.anai.2023.03.014_bib0036","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00281-021-00857-w","article-title":"What does elevated TARC\/CCL17 expression tell us about eosinophilic disorders?","volume":"43","author":"Catherine","year":"2021","journal-title":"Semin Immunopathol"},{"issue":"3","key":"10.1016\/j.anai.2023.03.014_bib0037","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jaci.2016.11.038","article-title":"Identification of airway mucosal type 2 inflammation by using clinical biomarkers in asthmatic patients","volume":"140","author":"Silkoff","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2023.03.014_bib0038","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nri3341","article-title":"Eosinophils: changing perspectives in health and disease","volume":"13","author":"Rosenberg","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"10.1016\/j.anai.2023.03.014_bib0039","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1016\/j.mayocp.2021.04.025","article-title":"Eosinophils in health and disease: a state-of-the-art review","volume":"96","author":"Wechsler","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.anai.2023.03.014_bib0040","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/2040622315609251","article-title":"Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease","volume":"7","author":"George","year":"2016","journal-title":"Ther Adv Chronic Dis"},{"issue":"1","key":"10.1016\/j.anai.2023.03.014_bib0041","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1182\/blood.V92.10.3904","article-title":"Eosinophil tethering to interleukin-4-activated endothelial cells requires both P-selectin and vascular cell adhesion molecule-1","volume":"92","author":"Patel","year":"1998","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.anai.2023.03.014_bib0042","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1182\/blood.V95.10.3146","article-title":"Interleukin-13 induces PSGL-1\/P-selectin-dependent adhesion of eosinophils, but not neutrophils, to human umbilical vein endothelial cells under flow","volume":"95","author":"Woltmann","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.anai.2023.03.014_bib0043","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3389\/fped.2018.00196","article-title":"Measuring airway inflammation in asthmatic children","volume":"6","author":"Tenero","year":"2018","journal-title":"Front Pediatr"},{"issue":"3","key":"10.1016\/j.anai.2023.03.014_bib0044","doi-asserted-by":"crossref","first-page":"1901633","DOI":"10.1183\/13993003.01633-2019","article-title":"Clinical utility of fractional exhaled nitric oxide in severe asthma management","volume":"55","author":"Menzies-Gow","year":"2020","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.anai.2023.03.014_bib0045","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/j.1365-2222.2008.02969.x","article-title":"IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells","volume":"38","author":"Chibana","year":"2008","journal-title":"Clin Exp Allergy"},{"issue":"2","key":"10.1016\/j.anai.2023.03.014_bib0046","doi-asserted-by":"crossref","first-page":"1802250","DOI":"10.1183\/13993003.02250-2018","article-title":"The interleukin-13 paradox in asthma: effective biology, ineffective biologicals","volume":"53","author":"Nair","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.anai.2023.03.014_bib0047","first-page":"A5949","article-title":"Type 2 biomarkers associated with dupilumab efficacy in patients with uncontrolled moderate-to-severe asthma enrolled in the phase 3 study LIBERTY ASTHMA QUEST","volume":"197","author":"Wenzel","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.anai.2023.03.014_bib0048","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.rmed.2010.02.006","article-title":"Sputum induction with hypertonic saline reduces fractional exhaled nitric oxide in chronic smokers and non-smokers","volume":"104","author":"Zuiker","year":"2010","journal-title":"Respir Med"},{"issue":"10","key":"10.1016\/j.anai.2023.03.014_bib49","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2174\/092986711795328436","article-title":"Exhaled nitric oxide in asthma in adults: the end is the beginning?","volume":"18","author":"Kostikas","year":"2011","journal-title":"Curr Med Chem"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120623001801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120623001801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:31:22Z","timestamp":1761053482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120623001801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1081120623001801"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2023.03.014","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2023.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}